ALI & Pulmonary HA Deposition After SAH
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Subarachnoid Haemorrhage (SAH). Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Relationship Between Acute Lung Injury and Pulmonary Hyaluronic Acid Deposition After Subarachnoid Hemorrhage
Overview
Acute lung injury is a common complication of subarachnoid hematoma (SAH), and a significant risk factor for death in patients with SAH. Unlike neurogenic pulmonary edema and pneumonia following brain injury, the clinical causes of pulmonary injury after SAH are not intracranial hypertension or pulmonary infection. Its occurrence is influenced by the release of catecholamines, the regulatory function of the hypothalamic-pituitary-adrenal (HPA) axis and systemic inflammatory response, but the specific mechanisms are still unclear. Therefore, delving into the pathological mechanisms of SAH-induced lung injury and developing therapeutic strategies based on the findings is of great importance to improve the prognosis of patients. Abnormal accumulation of hyaluronic acid in the lungs has been reported to be closely related to the pathological progression of various pulmonary injury diseases, such as chest trauma, pulmonary infection and chronic obstructive pulmonary disease. From this, the present research is aimed to explore the levels and dynamic changes of hyaluronic acid in the bronchoalveolar lavage fluid and blood of patients with acute lung injury following SAH, and to analyze its correlation with the prognosis of pulmonary complications, thereby providing assistance for the clinical diagnosis and treatment of SAH.
Primary outcome measures
- Hyaluronic acid level in bronchoalveolar lavage fluid after SAH [Time frame: During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH]
- Inflammatory cytokines levels in bronchoalveolar lavage fluid after SAH [Time frame: During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH]
Secondary outcome measures (2)
- Serum hyaluronic acid level after SAH [Time frame: During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH]
- Serum inflammatory cytokines levels after SAH [Time frame: During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH]
Eligibility criteria
Inclusion criteria
- Age between 18 and 80 years old with independent behavior ability or authorized legal representative.
- A documented diagnosis of SAH within 5 days.
- A Hunt-Hess scale of Ⅳ or Ⅴ.
- Absence of clinical and etiological evidence of pulmonary infection.
Exclusion criteria
- Pregnant or lactating women.
- Present history of traumatic brain injury or intracranial hemorrhage.
- Past history of neurological disorders, lung infection within the past six months, cancer, chronic cardiopulmonary diseases, hematological diseases or renal failure.
- Have participated in clinical trials in the past 4 weeks.
- The investigator considers that not appropriate for inclusion.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Tianjin Medical University General Hospital — Tianjin
Identifiers
NCT: NCT06628531 · IRB2024-YS-425-01